Kenneth E Sherman,David L Thomas
Kenneth E Sherman
Despite substantial advances in the field, liver disease morbidity and mortality remain serious issues among people with HIV. The causes of liver disease are often multifactorial and include hepatitis viruses, hepatic steatosis and oxidativ...
Hasiya Eihuri Yusuf,David Griffith,Allison Lorna Agwu
Hasiya Eihuri Yusuf
Adolescents with HIV are growing into adulthood and are at risk for comorbidities. Comorbidities in adolescents often go unrecognized, increasing morbidity and mortality, and contributing to poorer outcomes for youth with HIV. Youth with pe...
CROI 2022: tuberculosis and infectious complications in persons With HIV [0.03%]
CROI 2022：HIV感染者中的结核病和感染并发症
Andrew D Kerkhoff,Diane V Havlir
Andrew D Kerkhoff
Early treatment of anal high-grade squamous intraepithelial lesions compared with active monitoring reduced the risk of anal cancer by 57% in persons with HIV in a landmark randomized trial of 4446 participants. In a multi- country randomiz...
Randomized Controlled Trial
Topics in antiviral medicine. 2022 Oct-Nov;30(3):528-536. DOI: 2022
CROI 2022: metabolic and other complications of HIV infection or COVID-19 [0.03%]
CROI 2022:HIV感染或COVID-19的代谢和其他并发症
Sudipa Sarkar,Todd T Brown
Sudipa Sarkar
Comorbid conditions have a major impact on the health, quality of life, and survival of people with HIV, particularly as this population ages. The 2022 Conference on Retroviruses and Opportunistic Infections (CROI) featured excellent scienc...
CROI 2022: advances in antiviral therapy for HIV, COVID-19, and viral hepatitis [0.03%]
CROI 2022: 抗病毒治疗在HIV、COVID-19和病毒性肝炎方面的进展
Shauna H Gunaratne,Hong-Van Tieu,Timothy J Wilkin et al.
Shauna H Gunaratne et al.
The 2022 Conference on Retroviruses and Opportunistic Infections provided a rich source of new data and comprehensive reviews on antiviral therapy. For COVID-19, intramuscular sotrovimab was noninferior to intravenous sotrovimab, serostatus...
CROI 2022: neurologic complications of HIV-1, SARS-CoV-2, and other pathogens [0.03%]
CROI 2022：HIV-1、SARS-CoV-2和其他病原体引起神经并发症
Albert M Anderson,Scott L Letendre,Beau M Ances
Albert M Anderson
The 2022 Conference on Retroviruses and Opportunistic Infections featured new and important findings about the neurologic complications of HIV-1, COVID-19, and other infections. Long-term analyses identified that cognitive decline over time...
Randomized Controlled Trial
Topics in antiviral medicine. 2022 Oct-Nov;30(3):475-489. DOI: 2022
Update on tuberculosis/HIV coinfections: across the spectrum from latent infection through drug-susceptible and drug-resistant disease [0.03%]
结核病和HIV共感染的最新进展：从潜伏感染到药物敏感和耐药性疾病的各种表现
Elisa H Ignatious,Susan Swindells
Elisa H Ignatious
Tuberculosis (TB) remains the leading cause of death among people with HIV, and annual risk of progression from latent TB infection to active disease in this population is 10%. Diagnostic tests for latent and active TB remain suboptimal for...
Andres Fuenmayor,Francine Cournos
Andres Fuenmayor
Depressive disorders are the most common psychiatric disorders among people with HIV. Depressive disorders cause great suffering and disability and, among people with HIV, are associated with numerous negative HIV outcomes, including nonadh...
CROI 2022: epidemiologic trends and prevention for HIV and SARS-CoV-2 [0.03%]
CROI 2022：HIV和SARS-CoV-2的流行病趋势及预防措施
Susan Buchbinder,Albert Liu
Susan Buchbinder
At the 2022 Conference on Retroviruses and Opportunistic Infections, several speakers discussed disparities in HIV and COVID-19 infections and outcomes. Although the lifetime risk of HIV infection in the United States is higher overall in m...
CROI 2022: summary of basic science research in HIV and SARS-CoV-2 [0.03%]
CROI 2022:HIV和SARS-CoV-2基础研究总结
Mario Stevenson
Mario Stevenson
The Conference on Retroviruses and Opportunistic Infections (CROI) 2022, which was held as a virtual conference, continues to serve as the preeminent forum that features research advances in HIV-1 and its associated coinfections. The confer...